Please login to the form below

Not currently logged in
Email:
Password:

ABPI's Stephen Whitehead steps down

Leaves the UK pharma trade body after four years as its CEO

Stephen WhiteheadThe Association of the British Pharmaceutical Industry's (ABPI) Stephen Whitehead has left the organisation after serving as CEO for four years.

Speaking on behalf of the board ABPI president John Kearney said: “We want to thank Stephen for the very significant contribution he has made to the transformation and success of the ABPI.

“We wish Stephen the best for the future.”

Whitehead joined the UK trade body in 2011, taking over from Richard Barker, and brought senior experience from Barclays and Allied Domecq.

Earlier in his career, Whitehead spent ten years at GlaxoSmithKline and Eli Lilly at UK, European and international levels.

Once he moved back to pharma he quickly made an impact at the ABPI and in 2012 picked up Healthcare Communiquétor of the Year at the Communiqué Awards in recognition of his positive impact at the Association.

The ABPI said it would now begin searching for a new CEO and in the meantime Alison Clough would continue as acting CEO.

2nd October 2015

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics